Serrate Camille
Service d'oncologie médicale, GH Diaconesses Croix Saint-Simon, Paris, France.
Rev Prat. 2024 May;74(5):485-488.
THE ONCOLOGIST, DEATH AND THE PHARMAKON. Stopping chemotherapy for patients treated in oncology is a difficult moment, feared by oncologists because it is often associated with abandonment or even failure in front of a resistant or aggressive disease. End-of-life chemotherapy is still common in oncology departments. However, it will be harmful if it causes side effects which alter the quality of life of patients or even hasten their death. But above all, this chemotherapy delays the implementation of appropriate palliative care support. Questioning the risk of hubris (excess) in some treatment, asking the relationship between the patient and his death, and prioritizing the quality of last moments is essential to best support patients on the path to the end o f life.
肿瘤学家、死亡与药物。对于肿瘤科室接受治疗的患者而言，停止化疗是一个艰难时刻，肿瘤学家对此心怀恐惧，因为这往往与面对难治或侵袭性疾病时的放弃甚至失败相关联。临终化疗在肿瘤科室仍很常见。然而，如果它引发副作用，进而改变患者生活质量甚至加速其死亡，那便是有害的。但最重要的是，这种化疗会延误适当姑息治疗支持的实施。质疑某些治疗中存在的傲慢（过度）风险、探寻患者与其死亡之间的关系，以及将最后时刻的质量置于优先地位，对于在患者走向生命尽头的道路上给予最佳支持至关重要。
